Trasylol Clinical Benefit To Be Reviewed By FDA Advisory Committee

Cardiovascular & Renal Drugs Advisory Committee will also consider reports of hypersensitivity and renal and cardiovascular risk linked to Bayer’s aprotinin injection at its Sept. 21 meeting.